NASDAQ: APLTApplied Therapeutics Inc Stock
$0.85+0.01 (+1.19%)
Updated Mar 27, 2023
APLT Price
$0.85
Fair Value Price
$1.29
Market Cap
$40.66M
52 Week Low
$0.50
52 Week High
$2.73
P/E
-0.39x
P/B
10.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
8.45
Operating Cash Flow
-$78M
Beta
1.29
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
APLT Overview
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APLT ($0.85) is undervalued by 34.25% relative to our estimate of its Fair Value price of $1.29 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APLT ($0.85) is significantly undervalued by 34.25% relative to our estimate of its Fair Value price of $1.29 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APLT due diligence checks available for Premium users.
Be the first to know about important APLT news, forecast changes, insider trades & much more!
APLT News
Valuation
APLT fair value
Fair Value of APLT stock based on Discounted Cash Flow (DCF)
Price
$0.85
Fair Value
$1.29
Undervalued by
33.87%
APLT ($0.85) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APLT ($0.85) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.39x
Industry
18.55x
Market
21.44x
APLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.01x
Industry
4.86x
APLT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APLT's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.4M
Profit Margin
0%
APLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$38.4M
Liabilities
$34.3M
Debt to equity
8.45
APLT's short-term assets ($37.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APLT's short-term assets ($37.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.9M
Investing
-$6.9M
Financing
-$933.0k
APLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APLT vs Biotech Stocks
Applied Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.